---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-027449"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T17:01:20.563405+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Daré Bioscience Q2 2023 cash $13.3M; auditor resigns; Ovaprene Phase 3 enrollment to start 4Q23

## Summary
- Cash and cash equivalents of $13.3M at June 30, 2023; G&A expenses $2.9M, R&D expenses $6.0M.
- Auditor Mayer Hoffman McCann P.C. resigned effective upon filing of 2023 10-K or earlier; no disagreements; prior report had going concern paragraph.
- XACIATO first commercial sale expected 2H-2023; $1.0M cash received and $1.8M milestone upon first sale from partner Organon.
- Ovaprene pivotal Phase 3 contraceptive efficacy study enrollment to start 4Q-2023; U.S. rights licensed to Bayer.
- Sildenafil Cream 3.6% positive Phase 2b topline data; preparing end-of-Phase 2 FDA meeting for FSAD/FSIAD.

## SEC filing metadata
- accession: 0001493152-23-027449
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 4.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000149315223027449/0001493152-23-027449-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000149315223027449/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-027449
- JSON: https://secwatch.observer/filing/0001493152-23-027449.json
- Plain text: https://secwatch.observer/filing/0001493152-23-027449.txt

## Key facts
- Earnings Releases
  Dare Bioscience, Inc. reported financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: reported results
  source text: Daré Bioscience, Inc. (the “Company”), issued a press release announcing its financial results for the quarter ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401914/000149315223027449/0001493152-23-027449-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.